Mara Goldstein
Stock Analyst at Mizuho
(0.75)
# 2380
Out of 5,370 analysts
92
Total ratings
33.33%
Success rate
0.33%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
KURA Kura Oncology | Maintains: Outperform | 32 30 | 6.48 | 362.96% | 3 | May 19, 2025 | |
IOVA Iovance Biotherapeut... | Maintains: Outperform | 30 10 | 2.1 | 376.19% | 5 | May 12, 2025 | |
VSTM Verastem | Maintains: Outperform | 9 8 | 5.62 | 42.35% | 7 | Apr 9, 2025 | |
RCUS Arcus Biosciences | Maintains: Buy | 51 42 | 9.08 | 362.56% | 4 | Jan 30, 2024 | |
XNCR Xencor | Maintains: Buy | 59 50 | 9.05 | 452.49% | 2 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 45 | 9.97 | 351.35% | 1 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 82 77 | 71.13 | 8.25% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 8 7 | 1.41 | 396.45% | 3 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 12 8 | 1.23 | 550.41% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 20 12 | n/a | n/a | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 90 | 9.22 | 876.14% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 4 | 4.23 | -17.26% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 40 30 | n/a | n/a | 3 | May 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 360 | 2.2 | 16263.64% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 10 20 | 2.36 | 747.46% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 130 | 80.88 | 60.73% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 2 | 2.48 | -19.35% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 20 2 | n/a | n/a | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 18 12 | 2.04 | 488.24% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 9 | n/a | n/a | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 500 | n/a | n/a | 1 | Oct 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 13 10 | n/a | n/a | 2 | Sep 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 96 | n/a | n/a | 4 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 14 20 | 33.75 | -40.74% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 34 48 | 7.92 | 506.06% | 4 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 135 45 | 20.4 | 120.59% | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 22800 6000 | n/a | n/a | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 12 14 | 3.67 | 281.47% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 9 | n/a | n/a | 1 | Sep 14, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 15 | n/a | n/a | 1 | Jul 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 16 6 | n/a | n/a | 2 | Apr 18, 2017 |